Across Africa, funding constraints for research & development (R&D) are taking effect.
In Feb 2026, we convened experts to discuss the now urgent need to build a more equitable and sustainable R&D ecosystem in Africa.
Read our report 👉 msfaccess.org/shifting-glo...
Argentina has revoked key pharmaceutical patentability guidelines, a roll-back that could create and extend more monopolies, and, ultimately, delay or deny people’s access to affordable healthcare.
healthpolicy-watch.news/argentina-ha...
🦠 The impact of antimicrobial resistance (#AMR) in conflict-affected settings is severe.
The full report brings together practitioner experiences and offers ways to address AMR in some of the most fragile contexts, with lessons relevant worldwide. 👉 msfaccess.org/antimicrobia...
New MSF analysis sheds light on how monoclonal antibodies can increase protection for people after exposure to Ebola.
What’s needed now is more research and improved access to this promising treatment for healthcare workers and community members.
revuemtsi.societe-mtsi.fr/index.php/bs...
Under MSF's TACTiC initiative, the children were called to the MSF facility, where both Hareem and Ahmad were diagnosed with DR-TB. They are now receiving treatment at the clinic.
More about TACTiC 👉 www.msf.org/tactic-tuber...
Before the diagnosis, Hareem and Ahmad were often unwell. They had poor appetite, abdominal pain, irritability, and were becoming weak. Their mother had taken them to a nearby clinic where they were given medicines without proper diagnosis, but their condition did not improve.
"Previously, there were patients who fell into a borderline category. We suspected that the child had TB, but the tests did not show positive results. This algorithm has helped us a lot in such cases." Dr Saima Umar, Head of the Paediatrics Department at Gujranwala Teaching Hospital (Pakistan)
The Head of the Paediatrics Department at Gujranwala Teaching Hospital (Pakistan), Dr Saima Umar, shares her experience of how WHO Treatment Decision Algorithms are helping diagnose children with #tuberculosis more effectively and the challenges doctors faced before their introduction.
Despite Gilead’s public claims that it can expand production of lenacapavir to meet needs, the company has refused requests from MSF to purchase a limited supply for use in our programs.
Read our open letter to Gilead here: www.doctorswithoutborders.org/latest/preve...
NEW: US pharmaceutical corporation Gilead Sciences is refusing to sell groundbreaking HIV prevention drug to MSF.
“The tools to diagnose and treat children with TB exist, even if imperfect, yet only half of the children who have TB are diagnosed or treated. For a truly global TB response, children must be prioritised now,” said Cathy Hewison, TB working group lead, MSF.
The conclusions in our report, “Antimicrobial resistance in conflict-affected settings,” can help guide people-centered responses to AMR while recognising the resource limitations, operational constraints, and unpredictability of humanitarian settings.
msfaccess.org/antimicrobia...
“We’re seeing everything coming together at once: contexts becoming more complex and crises increasingly compounded, multi-layered and protracted. Given these constraints, Infection Prevention and Control, antimicrobial stewardship and microbiology are key essential strategies to provide quality care.” -- Dr Kalyan Velivela, MSF health programme manager for South Sudan, Ethiopia, and Nigeria.
“AMR in conflict or humanitarian settings is right there. It’s in front of us. We're already dealing with it.” Dr Kalyan Velivela, MSF health programme manager for South Sudan, Ethiopia, and Nigeria.
Addressing AMR in humanitarian settings means acting on our shared experiences.
On #WorldTBDay, MSF urges governments and donors to put children at the heart of the global TB response. Sustained funding is needed to diagnose, treat, and prevent TB in children, who remain one of the most vulnerable groups.
msfaccess.org/msf-demands-...
Why half of the 1.2 million children with TB cannot access diagnosis and lifesaving treatment? Watch this video to learn more. #WorldTBDay
www.youtube.com/watch?v=6k6Y...
Drawing on MSF’s frontline experience across emergencies, we’re calling on EU to progress towards a system that ensures fair and equitable benefit‑sharing in exchange for access to pathogens and genetic resources used in R&D, including clinical trials.
msfaccess.org/msf-calls-eu...
“We hope the positive elements of the intellectual property in the EU-India trade agreement serve as a template for other countries, enabling them to resist pressure during trade negotiations and safeguard access to affordable medicines,” added Sarathi Rajendran, Executive Director, MSF South Asia.
“We call on Government of India to ensure careful implementation of the enforcement and trade secret provisions which will be crucial to maintaining these hard-earned gains,” warned Roshan Joseph, Legal and Policy Advisor, MSF Access.
"After two decades of determined resistance by affected communities and civil society, this moment marks a hard-fought victory. The exclusion of data exclusivity and patent term extension from Intellectual Property chapter are not abstract legal victories: they ensure that medicines do not remain out of reach for years after patents expire." Loon Gangte, President, Delhi Network of Positive People
The intellectual Property chapter of this trade deal largely preserves India’s public health safeguards and does not include any harmful provisions that go beyond the World Trade Organization’s TRIPS agreement, such as data exclusivity or patent term extensions.
In 2011, more than 3,000 people marched in India to oppose harmful provisions that could have been included in EU–India free trade agreement and threatened access to affordable medicines. Fifteen years later, after two decades of sustained advocacy, those were excluded from the final deal.
👎Some provisions may impact generic competition and hence require careful consideration.
Read our full reaction: msfaccess.org/dnp-and-msf-...
India-EU free trade agreement full text has been released and the intellectual property chapter:
👍Largely preserves India’s public health safeguards and doesn't go beyond @wto.org TRIPS agreement
🛑 BUT 🛑
In 2014, I visited eastern DRC, where @msf.org teams were treating sleeping sickness - the only available treatment was a drug so toxic it killed 1 in 20 patients. In 2026 I'm so proud that, thanks to @dndi.org, patients can be cured with a single dose of a groundbreaking new oral drug, acoziborole.
🚀 Huge news for people living with #sleepingsickness!
Acoziborole, a one-day, single-dose oral treatment developed with Sanofi, has received a positive opinion from @ema.europa.eu for the treatment of the most common form of sleeping sickness.
👉 bit.ly/46ZFpEi
Thanks @madhupai.bsky.social for the spotlight on TB in Europe. Additionally, lack of access to treatment due to unavailability, high prices, and fragmented supply of TB medicines remains a major challenge. Critical DR-TB meds are exorbitantly priced in the region: some over 100x than in LMICs!
From outbreaks to pandemics, MSF has repeatedly seen patients and communities, who contribute vital samples, data and clinical participation to lifesaving innovations, being denied access to the very products they help make possible. PABS system must guarantee access for all.
Read MSF’s recommendations for a strong WHO Pathogen Access and Benefit-Sharing (PABS) system calling for reliable, equitable and accountable access to vaccines, diagnostics and treatments developed from shared samples and data. msfaccess.org/ensuring-col...
Weakening safeguards for research participants sends a dangerous global signal — especially as countries negotiate at the WHO on an agreement on research and access during health emergencies.
MSF has already warned that this law marks a serious rollback of protections for people who volunteer in clinical trials and has urged the Brazilian government to reverse course msfaccess.org/msf-denounce...
👉 @msfbrasil.bsky.social is seeking to intervene in a Supreme Court case challenging Brazil’s new law on research, which limits the right of clinical trial participants to receive free access to medicines developed from the studies they joined.
Vaccines: Most un- and under-vaccinated children live in fragile, conflict-affected contexts, where systemic barriers keep vaccination coverage low. Governments, donors and health actors must ramp up immunisation in these settings and ensure funding gaps do not compromise equity.
